In Silico Clinical Trials Market Report 2026

The in silico clinical trials market size has grown rapidly in recent years. It will grow from $3.74 billion in 2025 to $4.11 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to high cost of traditional clinical trials, long drug development timelines, increasing use of computational modeling, need for improved trial efficiency, growth of medical device innovation.

The in silico clinical trials market size is expected to see rapid growth in the next few years. It will grow to $6.14 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to rising adoption of AI driven simulations, regulatory acceptance of virtual evidence, demand for faster clinical validation, expansion of personalized medicine, increasing R&D investment by pharma companies. Major trends in the forecast period include virtual patient modeling, simulation based trial design, digital twin clinical testing, predictive safety assessment, computational drug evaluation.

The growing need to curb clinical trial costs is expected to propel the growth of the in silico clinical trials market going forward. Clinical trial costs refer to the expenses associated with planning, conducting, and managing a clinical trial to test the safety, efficacy, and potential benefits of a new medical intervention, such as a drug, medical device, or treatment protocol. Traditional clinical trials are a lengthy and expensive process, often taking 10-15 years and costing billions of dollars to bring a new drug to market. In silico clinical trials offer a promising alternative, using computer simulations to test the safety and efficacy of drugs and medical devices. For instance, in February 2023, according to Genetic Engineering and Biotechnology News, a US-based platform that provides the latest information on genetic engineering and biotechnology, developing a new drug among the top 20 global biopharma companies rose by 15%, from $298 million in 2022 to approximately $2.3 billion in 2023, and this includes the costs incurred from developing a drug through clinical trials. Therefore, the growing need to curb clinical trial costs will drive the in silico clinical trial market.

Major companies operating in the in silico clinical trials market are emphasizing innovative technologies, such as clinical trial platforms, to maintain their market presence. A clinical trial platform is a specialized form of adaptive, disease-specific, randomized clinical trial (RCT) designed to assess multiple simultaneous interventions against a single, consistent control group. For instance, in October 2023, Advarra, a US-based provider of regulatory review solutions and clinical research technology for sites and sponsors, introduced Longboat v2.2, a new technological enhancement aimed at improving the clinical trial experience for all stakeholders. Longboat, a well-established platform used across more than 70 countries and by nearly 20,000 sites, now includes an online patient portal equipped with a comprehensive range of engagement tools, including a streamlined document exchange feature that enables transparent collaboration between patients, sites, and sponsors or clinical research organizations (CROs) without adding additional technology burden.

In May 2023, Recursion, a US-based clinical-stage TechBio company, disclosed the acquisition of Cyclica and Valence for an undisclosed sum. These strategic acquisitions bring cutting-edge capabilities in digital chemistry, as well as machine learning and artificial intelligence from Cyclica and Valence. These capabilities are seamlessly integrated with Recursion's extensive automated wet-laboratories and supercomputing resources. This integration positions Recursion to deploy the most comprehensive, technology-enabled drug discovery solution within the biopharma industry. Cyclica, a biotechnology company based in Canada, and Valence, a Canadian deep learning research institute, collectively contribute to enhancing Recursion's capabilities in the pursuit of advancing drug discovery through innovative technologies.

Major companies operating in the in silico clinical trials market are Dassault Systemes SE; Evotec A.G; Evidera; Certara Inc.; Simulations Plus Inc.; Insilico Medicine Inc.; AnyLogic Company; Biomax Informatics; GNS Healthcare Inc.; 4P-Pharma; Nuventra Pharma Sciences; Archimedes; Novadiscovery Sas; Rosa & Co.; In Silico Biosciences; Leadscope; Biognos Ab; BioNova; Immunetrics Inc.; InSilicoTrials; Physiomics plc; Entelos; InhibOx; Selvita; Abzena Limited.

North America was the largest region in the in silico clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the in silico clinical trials market report during the forecast period. The regions covered in the in silico clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in silico clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the in silico clinical trials market by increasing costs related to high performance computing infrastructure, specialized software licenses, and cross border data services. These cost challenges have influenced adoption among small research organizations, particularly in emerging markets dependent on imported digital infrastructure. Pharmaceutical and medical device segments in north america and europe have experienced moderate pricing pressure. At the same time, tariffs have accelerated local software development, cloud based simulation platforms, and regional digital health ecosystems, supporting long term market growth.

The in silico clinical trials market research report is one of a series of new reports that provides in silico clinical trials market statistics, including in silico clinical trials industry global market size, regional shares, competitors with a in silico clinical trials market share, detailed in silico clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the in silico clinical trials industry. This in silico clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In silico clinical trials, also known as virtual clinical trials, involve computer simulations used to develop or evaluate the safety and efficacy of medicinal products, devices, or interventions. They serve as a method to assess the safety and effectiveness of medical devices and imaging systems.

The primary phases of in silico clinical trials include Phase I, Phase II, Phase III, and Phase IV. Phase I represents the initial evaluation of a drug or treatment on a small group of people, aiming to assess the safety and tolerability of new drugs in humans. These trials are conducted across various medical domains such as oncology, infectious disease, hematology, cardiology, dermatology, neurology, diabetes, and others. In silico clinical trials find applications in both the medical devices and pharmaceutical industries.

The in silico clinical trials market includes revenues earned by entities by providing services such as data management, trial design, information compilation and site support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.